知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1664 条记录 (耗时 0.045 秒)

    Methods and compositions concerning poxviruses and cancer
    21.
    发明授权
    Methods and compositions concerning poxviruses and cancer 有权
    关于痘病毒和癌症的方法和组成

    公开(公告)号：US08986674B2

    公开(公告)日：2015-03-24

    申请号：US13675953

    申请日：2012-11-13

    申请人： Jennerex, Inc.

    发明人： David Kirn ,  Steve H. Thorne

    IPC分类号： A61K39/275 ,  C12N7/00 ,  C12N15/86 ,  A61K38/21 ,  A61K45/06 ,  C12N7/01 ,  A61K48/00

    CPC分类号： A61K35/768 ,  A61K38/21 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24143 ,  C12N2710/24161 ,  C12N2710/24162 ,  A61K2300/00

    摘要： The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.

    摘要翻译： 本发明涉及使用改变的痘病毒治疗癌症和癌细胞的方法和组合物，其包括已被改变以产生更有效治疗剂的痘苗病毒。 这种痘病毒被设计为在影响正常细胞的能力方面被减弱或削弱。 在一些实施方案中，方法和组合物涉及具有导致痘病毒的突变的痘病毒，其具有减少或消除在宿主中实施抗病毒反应的能力。 具有这些突变与其它突变组合的痘病毒可用于更有效地治疗癌症。

    Targeting of herpes simplex virus to specific receptors
    25.
    发明授权
    Targeting of herpes simplex virus to specific receptors 有权
    将单纯疱疹病毒靶向特异性受体

    公开(公告)号：US08927251B2

    公开(公告)日：2015-01-06

    申请号：US12065455

    申请日：2006-08-30

    申请人： Guoying Zhou ,  Bernard Roizman

    发明人： Guoying Zhou ,  Bernard Roizman

    IPC分类号： C12N7/01 ,  C12N15/869 ,  A61K39/245 ,  A61K49/00 ,  A61K47/48 ,  A61K38/20 ,  C12Q1/70

    CPC分类号： C07K16/18 ,  A61K35/00 ,  A61K38/2086 ,  A61K47/642 ,  A61K47/6801 ,  A61K47/69 ,  A61K47/6901 ,  C07K14/5437 ,  C12N15/86 ,  C12N15/8695 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2799/028 ,  C12N2810/50 ,  C12N2810/852 ,  C12Q1/705

    摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

    摘要翻译： 本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。 此外，提供了用于生产这种HSV颗粒的重组载体。 通过降低HSV对其天然受体的亲合力并增加对选定受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。 选择性靶向细胞的能力使HSV颗粒。 特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员例如受体的细胞。 本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

    Raav expression systems for genetic modification of specific capsid proteins
    27.
    发明授权
    Raav expression systems for genetic modification of specific capsid proteins 有权
    用于特异性衣壳蛋白遗传修饰的Raav表达系统

    公开(公告)号：US08802080B2

    公开(公告)日：2014-08-12

    申请号：US10513059

    申请日：2003-05-01

    申请人： Kenneth H. Warrington ,  Shaun R. Opie ,  Nicholas Muzyczka

    发明人： Kenneth H. Warrington ,  Shaun R. Opie ,  Nicholas Muzyczka

    IPC分类号： C12N15/864 ,  C12N7/01 ,  C12N5/10 ,  C12N15/63 ,  C07K14/015

    CPC分类号： A61K48/005 ,  C07K14/005 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2810/50 ,  C12N2810/858

    摘要： Disclosed are improved recombinant adeno-associated viral (rAAV) vectors having mutations in one or more capsid proteins. Exemplary vectors are provided that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations that comprise them useful in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.

    摘要翻译： 公开了在一种或多种衣壳蛋白中具有突变的改良的重组腺相关病毒（rAAV）载体。 提供了对肝素或硫酸肝素具有改变的亲和力的示例性载体，以及缺乏功能性VP2蛋白表达但仍然是完全毒性的载体，表达系统和rAAV病毒体。 本发明还提供了基于rAAV载体的组合物，病毒颗粒，宿主细胞和药物制剂，其包含它们可用于选择的哺乳动物（包括器官）中选择的治疗性蛋白质，多肽，肽，反义寡核苷酸和/或核酶的表达， 组织和人宿主细胞。

    Plant virus-based inducible expression system
    29.
    发明授权
    Plant virus-based inducible expression system 有权
    植物病毒诱导表达系统

    公开(公告)号：US08624080B2

    公开(公告)日：2014-01-07

    申请号：US12301156

    申请日：2007-05-25

    申请人： Stefan Werner ,  Sylvestre Marillonnet ,  Victor Klimyuk ,  Yuri Gleba

    发明人： Stefan Werner ,  Sylvestre Marillonnet ,  Victor Klimyuk ,  Yuri Gleba

    IPC分类号： C12N15/40 ,  C12N15/79 ,  C12N15/83 ,  C12N7/01 ,  A01H5/00

    CPC分类号： C12N15/8238

    摘要： A process of producing one or more than one protein of interest, comprising: (a) providing a plant or plant cells comprising a first heterologous nucleotide sequence comprising a nucleotide sequence encoding an RNA replicon, and a first inducible promoter operably linked to said nucleotide sequence encoding said RNA replicon; said RNA replicon not encoding a protein providing for cell-to-cell movement of said RNA replicon in said plant; said RNA replicon encoding a polymerase and said one or more than one protein of interest, said polymerase being adapted for replicating said RNA replicon; and (b) inducing, in said plant or plant cells of step (a), said inducible promoter, thereby producing said one or more than one protein of interest in said plant or plant cells.

    摘要翻译： 一种产生一种或多于一种感兴趣的蛋白质的方法，包括：（a）提供包含第一异源核苷酸序列的植物或植物细胞，所述第一异源核苷酸序列包含编​​码RNA复制子的核苷酸序列，和与所述核苷酸序列可操作地连接的第一诱导型启动子 编码所述RNA复制子; 所述RNA复制子不编码提供所述植物中所述RNA复制子的细胞与细胞运动的蛋白质; 所述RNA复制子编码聚合酶和所述一种或多种感兴趣的蛋白质，所述聚合酶适于复制所述RNA复制子; 和（b）在所述植物或植物细胞中诱导所述诱导型启动子，从而在所述植物或植物细胞中产生所述一种或多种感兴趣的蛋白质。

    Cells and methodology to generate non-segmented negative-strand RNA viruses
    30.
    发明授权
    Cells and methodology to generate non-segmented negative-strand RNA viruses 有权
    产生非分段负链RNA病毒的细胞和方法

    公开(公告)号：US08586364B2

    公开(公告)日：2013-11-19

    申请号：US12448468

    申请日：2007-12-21

    申请人： Frédéric Tangy ,  Pierre Charneau ,  Yves Jacob

    发明人： Frédéric Tangy ,  Pierre Charneau ,  Yves Jacob

    IPC分类号： C12N7/01 ,  C12N7/02 ,  C12N7/04 ,  A61K39/165

    CPC分类号： C12N7/00 ,  C07K14/005 ,  C12N15/86 ,  C12N2740/16021 ,  C12N2740/16043 ,  C12N2740/16052 ,  C12N2760/18022 ,  C12N2760/18422 ,  C12N2830/48

    摘要： The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.

    摘要翻译： 本发明涉及重组细胞，以及用于从克隆的脱氧核糖核酸（cDNA），特别是麻疹病毒，特别是从减毒菌株中产生非分段的负义单链RNA病毒（NNV或单酮巴西）的方法 例如批准用于疫苗接种的那些，特别是来自减毒的施瓦氏麻疹病毒和表达异源序列的各种重组Schwarz麻疹病毒。 这样的拯救病毒可以在扩增后用作针对麻疹免疫的疫苗和/或针对所表达的异源肽或蛋白质。